About Us
Jerini focuses on the discovery, development, and commercialization of novel peptide-based drugs. The company selectively pursues disease indications for which patients have limited or no treatment options.
Facts
- Started operations in 1994
- 170 employees
- European Marketing Authorization for Firazyr® (Icatibant) in the Treatment of HAE
- Proprietary Peptides-to-Drugs (P2D) technology platform specializing in the
systematic transformation of peptides into peptidomimetic and small molecule drugs - Broad drug pipeline in clinical and preclinical phases
- Profitable subsidiary: JPT Peptide Technologies GmbH (JPT)
- Wholly-owned subsidiary Jerini Ophthalmic, Inc. for the development of ophthalmology compounds
print
Recommend this page
Top